Updated results of the Tide-A study evaluating avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients with metastatic renal cell carcinoma (mRCC).

• DOI: 10.1200/jco.2025.43.5_suppl.551
• Publication Date: 2025-02-18T14:35:11Z
• Authors: Daniela Arduini; Chiara Ciccarese; Alessandro Acunzo; Matteo Perrino; Marco Maruzzo; Elena Verzoni; Caterina Accettura; Lucia Bonomi; Consuelo Buttigliero; Malvina Cremante; Stefania Pipitone; Mario Scartozzi; Cristina Masini; Veronica Mollica; Francesca Primi; Alessandro Strusi; Sebastiano Buti; Paolo Andrea Zucali; Emanuela Fantinel; Roberto Iacovelli
• Keywords: Axitinib; Avelumab

551 Background: Combinations of therapies with VEGFR-TKI (TKI) and anti-PD1/PDL1 immunotherapy (IO) are considered the standard care for first line treatment patients (pts) mRCC. The Tide-A trial previously reported feasibility TKI interruption maintenance in pts achieving tumor response after TKI+IO combination, its primary endpoint. Here we updated results a longer follow-up. Methods: Pts surgery tumor, without symptomatic/bulky disease or liver mets, were treated Ave 800 mg flat dose IV Q2W + Axi 5 PO BID 36 weeks (W). At W36, who achieved partial (PR) interrupted continued until progression (PD) unacceptable toxicity. In case PD while on Ave, was restarted again new PR. PR at W36 continue combo PD. mPFS mOS overall population those Axi. outcome reintroduction also described. Results: 75 evaluated efficacy analysis (40% favorable risk, 60% intermediate/poor risk). cutoff data Apr 2024, median follow up 31.7 mos, 27.9 mos (95%CI, 23.0 - 32.8) not reached 24-mos OS rate 85%. duration 1 st avelumab 16 weeks. Among 29 reached; PFS rates 68% 82%, respectively. After ongoing evidence PD; discontinued toxicity 35.8 maintenance; 2 alone despite PD;21 these 21 pts, restart axitinib, ORR 50% (10 PR; 8 SD; pt NA), 17.2 11.9 – 22.5). Conclusions: Updated TIDE-A study confirmed IO selected mRCC initial to combination plus during did affect subsequent reintroduction. This strategy warrants further investigation randomized trial. Clinical information: NCT04698213 .